Ribomic Inc. | Cash Flow

Fiscal year is April-March. All values JPY Thousands.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
210,881.00
11,646.00
322,103.00
645,393.00
751,838.00
835,414
Depreciation, Depletion & Amortization
11,994.00
18,109.00
13,753.00
35,809.00
25,606.00
27,503
Other Funds
-
7,880.00
-
3,765.00
303.00
9,840
Funds from Operations
203,521.00
96,000.00
306,849.00
622,589.00
718,662.00
798,073
Changes in Working Capital
40,996.00
38,584.00
17,854.00
84,305.00
23,865.00
32,391
Net Operating Cash Flow
162,525.00
134,584.00
324,703.00
706,894.00
694,797.00
830,464
Capital Expenditures
36,877.00
2,561.00
47,960.00
30,073.00
14,835.00
Purchase/Sale of Investments
99,999.00
1,300,000.00
115,120.00
624,126.00
996,214.00
Net Investing Cash Flow
63,122.00
1,302,561.00
1,362,422.00
594,052.00
958,825.00
Net Financing Cash Flow
1,500.00
2,871,586.00
98,928.00
45,899.00
534,568.00
Net Change in Cash
97,885.00
1,706,342.00
1,588,197.00
66,862.00
797,101.00
Free Cash Flow
199,082.00
132,023.00
372,663.00
736,798.00
709,133.00
Net Assets from Acquisitions
-
-
-
-
22,552.00
Change in Capital Stock
1,500.00
2,879,466.00
98,928.00
42,134.00
534,265.00
Exchange Rate Effect
18.00
2,733.00
-
81.00
1,495.00

About Ribomic

View Profile
Address
Shirokanedai Usui Building, 6/F
Tokyo Tokyo 108
Japan
Employees -
Website http://www.ribomic.com/
Updated 07/08/2019
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. It utilizes RiboART system, a platform technology essentially applicable to any target proteins, and not limited to disease. The company was founded by Yoshikazu Nakamura on August 1, 2003 and is headquartered in Tokyo, Japan.